Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of tSVFem (tSVFem)
Primary Purpose
Gastrointestinal Fistula
Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
injection of emulsified adipose tissue stromal vascular fraction
Sponsored by

About this trial
This is an interventional treatment trial for Gastrointestinal Fistula focused on measuring gastrointestinal fistula, Adipose-derived stem cells, adipose tissue stromal vascular fraction, Endoscopy
Eligibility Criteria
Inclusion criteria:
• Patients affected by GI fistulas, not fit for surgical treatments of after failure of conventional conservative treatments
Exclusion Criteria:
- Enteroenteric fistulas
- Patients who do not sign informed consent form
Sites / Locations
- Fondazione Policlinico Agostino Gemelli IRCCSRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Experimental arm
Arm Description
Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
Outcomes
Primary Outcome Measures
Fistula healing
Rate of healing of fistula at endoscopy and gastrografin swallow
Secondary Outcome Measures
Incidence of treatment adverse events and complications
To evaluate the percentage of patients that developed adverse events or any complications during and after the treatment proposed
Full Information
NCT ID
NCT04670276
First Posted
December 3, 2020
Last Updated
December 10, 2020
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1. Study Identification
Unique Protocol Identification Number
NCT04670276
Brief Title
Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of tSVFem
Acronym
tSVFem
Official Title
Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of Emulsified Adipose Tissue Stromal Vascular Fraction (tSVFem)
Study Type
Interventional
2. Study Status
Record Verification Date
December 2020
Overall Recruitment Status
Unknown status
Study Start Date
November 2, 2020 (Actual)
Primary Completion Date
March 2, 2022 (Anticipated)
Study Completion Date
April 10, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Gastrointestinal (GI) fistula is a complex condition with high mortality and requiring a multidisciplinary management.
The aim of this study is to exploit the regenerative-tissue capacities of autologous emulsified adipose tissue-derived stromal vascular fraction (tSVFem, widely used in other medical fields - like plastic surgery -for different purposes) harvested and delivered locally by endoscopy to close the GI fistula.
The proposed technique for the treatment of GI fistulas with tSVFem requires a minimal, inexpensive, easily reproducible mechanical manipulation of autologous adipose tissue without necessity of any enzymatic digestion or cell expansion.
Detailed Description
Gastrointestinal fistula may be a life-threatening condition caused by several types of injuries (iatrogenic, traumatic, post-operative), requiring complex and multidisciplinary management. To date, no clear guidelines have been drawn up for the treatment, that may include a conservative, minimally invasive, or major surgical approach depending on the patient's specific clinical characteristics. Furthermore, patients with fistulas are often fragile, and surgical treatments are highly risky and invasive. Less invasive treatments such as stenting, endoluminal endoscopic vacuum therapy and suturing are widely employed, but these treatments often require long hospitalization, highly skilled operators, without certain results and with high rates of complications.
The aim of this study is to exploit the regenerative-tissue capacities of autologous emulsified adipose tissue-derived stromal vascular fraction (tSVFem, widely used in other medical fields - like plastic surgery -for different purposes) harvested and delivered locally by endoscopy to close the GI fistula. Indeed, the anti-inflammatory and regenerative-tissue promoting effects of tSVFem may safely promote rapid and effective tissue healing as alternative, and in this setting they were not investigated before. Fistulas are often long-standing chronic conditions, thus healing mechanisms are delayed and subverted in favor of inflammation and fibrosis, resembling chronic inflammatory diseases. Delivery of tSVFem is a promising new approach that promotes healing in virtue of its immunosuppressive, immunomodulatory, pro-angiogenic and regenerative potentials. Since the grafted material used in this study is autologous, there is no risk for rejection. All the procedures are performed under general anesthesia with orotracheal intubation or laryngeal mask. Approximately 30 cc of fat are harvested from the superficial layer of subcutaneous tissue by a 2.1 mm microcannula with 4, 1-mm size holes, arranged in a single raw, to get the so-called "microfat". Twenty cc of the harvested microfat are mechanical emulsified by sequential passages through 2.4mm and 1.2mm filters, and a 600/400 μm disposable filtering device.
Then the material is centrifuged at 3000 rounds for three minutes, obtaining the tSVFem after removal of supernatant fraction and oil released upon mature adipocytes mechanical disruption.
Subsequently, an endoscopy is performed to inject 10 cc of microfat into the fistula (through a 6-French catheter) until it was completely filled. Then, with a 22 Gauge endoscopic needle, a total of 1-2 cc of tSVFem were injected into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
A radiologic and endoscopic control at day-7 is done to evaluate complete healing of the fistula.
The technique proposed by the investigators for the treatment of GI fistulas with tSVFem requires a minimal, inexpensive, easily reproducible mechanical manipulation of autologous adipose tissue without necessity of any enzymatic digestion or cell expansion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Fistula
Keywords
gastrointestinal fistula, Adipose-derived stem cells, adipose tissue stromal vascular fraction, Endoscopy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental arm
Arm Type
Experimental
Arm Description
Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
Intervention Type
Procedure
Intervention Name(s)
injection of emulsified adipose tissue stromal vascular fraction
Intervention Description
Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
Primary Outcome Measure Information:
Title
Fistula healing
Description
Rate of healing of fistula at endoscopy and gastrografin swallow
Time Frame
7 days after the injection procedure of tSVFem
Secondary Outcome Measure Information:
Title
Incidence of treatment adverse events and complications
Description
To evaluate the percentage of patients that developed adverse events or any complications during and after the treatment proposed
Time Frame
During the procedure, 7 days after and at 1-2 month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria:
• Patients affected by GI fistulas, not fit for surgical treatments of after failure of conventional conservative treatments
Exclusion Criteria:
Enteroenteric fistulas
Patients who do not sign informed consent form
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dania Nachira, MD
Phone
00390630155692
Email
dania.nachira@policlinicogemelli.it
First Name & Middle Initial & Last Name or Official Title & Degree
Dania Nachira
Phone
00390630155692
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Venanzio Porziella, MD
Organizational Affiliation
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fondazione Policlinico Agostino Gemelli IRCCS
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Venanzio Porziella
Phone
00390630156353
Email
Venanzio.porziella@policlinicogemelli.it
First Name & Middle Initial & Last Name & Degree
Venanzio Porziella, MD
First Name & Middle Initial & Last Name & Degree
Dania Nachira, MD
First Name & Middle Initial & Last Name & Degree
Ivo Boskoski, MD
First Name & Middle Initial & Last Name & Degree
Angelo Trivisonno, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
15063302
Citation
Brinster CJ, Singhal S, Lee L, Marshall MB, Kaiser LR, Kucharczuk JC. Evolving options in the management of esophageal perforation. Ann Thorac Surg. 2004 Apr;77(4):1475-83. doi: 10.1016/j.athoracsur.2003.08.037.
Results Reference
background
PubMed Identifier
32634381
Citation
Porziella V, Nachira D, Boskoski I, Trivisonno A, Costamagna G, Margaritora S. Emulsified stromal vascular fraction tissue grafting: a new frontier in the treatment of esophageal fistulas. Gastrointest Endosc. 2020 Dec;92(6):1262-1263. doi: 10.1016/j.gie.2020.06.019. Epub 2020 Jul 4. No abstract available.
Results Reference
background
PubMed Identifier
28078463
Citation
Kuehn F, Loske G, Schiffmann L, Gock M, Klar E. Endoscopic vacuum therapy for various defects of the upper gastrointestinal tract. Surg Endosc. 2017 Sep;31(9):3449-3458. doi: 10.1007/s00464-016-5404-x. Epub 2017 Jan 11.
Results Reference
background
PubMed Identifier
23733727
Citation
Brangewitz M, Voigtlander T, Helfritz FA, Lankisch TO, Winkler M, Klempnauer J, Manns MP, Schneider AS, Wedemeyer J. Endoscopic closure of esophageal intrathoracic leaks: stent versus endoscopic vacuum-assisted closure, a retrospective analysis. Endoscopy. 2013 Jun;45(6):433-8. doi: 10.1055/s-0032-1326435. Epub 2013 Jun 3.
Results Reference
background
PubMed Identifier
32363193
Citation
Ceccarelli S, Pontecorvi P, Anastasiadou E, Napoli C, Marchese C. Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. Front Cell Dev Biol. 2020 Apr 17;8:236. doi: 10.3389/fcell.2020.00236. eCollection 2020.
Results Reference
background
Citation
Angelo Trivisonno, Marc Abecassis, Massimo Monti et al. Adipose Tissue: From Energy Reservoir to a Source of Cells for Epithelial Tissue Engineering. In: Stem Cells in Aesthetic Procedures: Springer Berlin Heidelberg,2014:303-326
Results Reference
background
PubMed Identifier
31942308
Citation
Trivisonno A, Nachira D, Boskoski I, Calcagni F, Tringali A, Costamagna G, Margaritora S, Porziella V. Autologous Fat Grafting Restores Soft-tissue Contour Deformities after Vascular Anomaly: Widening the Horizons of Employment of Autologous Fat Grafting. Plast Reconstr Surg Glob Open. 2019 Nov 27;7(11):e2518. doi: 10.1097/GOX.0000000000002518. eCollection 2019 Nov. No abstract available.
Results Reference
background
PubMed Identifier
27477896
Citation
Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.
Results Reference
background
Learn more about this trial
Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of tSVFem
We'll reach out to this number within 24 hrs